Answers are grounded in this paper and cite their sources.
Our study is the first to report TT in EPCTs with an extended follow-up. Clinicians should be aware of TT when discussing risks and benefits. TT also may not be the appropriate term when describing the time patients invest during EPCTs. Toxicity implies a negative impact, but for many patients, trial participation would be seen as positive. There should be efforts to streamline health care visits to limit TT in EPCTs.
No takes yet. Share an insight, caveat, or question.
Nindra et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: